Aeovian Pharmaceuticals Secures $55M Series B Funding

Why It Matters

The infusion of $55 M accelerates development of a first‑in‑class mTORC1 inhibitor, addressing a high‑unmet‑need rare disease and positioning Aeovian for future partnership or exit opportunities.

Key Takeaways

• $55M Series B funding secured.
• Luma Group and CTI lead the round.
• AV078 moves to Phase 2 for TSC epilepsy.
• Board adds Luma and CTI partners.
• Targeting mTORC1 pathway in rare genetic disorder.

Pulse Analysis

The biotech financing landscape in 2025 continues to favor companies tackling rare, high‑unmet‑need indications, and Aeovian’s $55 million Series B exemplifies this trend. Led by strategic investors Luma Group and CTI Life Sciences Fund, the round reflects confidence in the firm’s scientific platform and its ability to attract follow‑on capital. Participation from specialty funds such as the TSC Alliance Endowment underscores a growing alignment between disease‑focused philanthropy and venture capital, creating a robust funding pipeline for niche therapeutic areas.

AV078, Aeovian’s lead candidate, is a CNS‑penetrant, selective mTORC1 inhibitor designed to restore cellular metabolic quality control. In tuberous sclerosis complex (TSC), hyperactive mTORC1 signaling drives refractory epilepsy, a condition with limited treatment options. By directly targeting this pathway, AV078 offers a mechanistic advantage over existing antiseizure drugs, potentially delivering disease‑modifying benefits. The upcoming Phase 2 trial will evaluate efficacy and safety in patients who have failed conventional therapies, a critical step toward regulatory approval and market entry.

If AV078 demonstrates clinical success, Aeovian could capture a valuable segment of the rare‑disease neurology market, projected to exceed several hundred million dollars annually. The addition of Luma and CTI executives to the board brings deep expertise in drug development and commercialization, enhancing the company’s strategic positioning for future partnerships or an IPO. Moreover, the funding enables scale‑up of manufacturing and broader preclinical programs, reinforcing Aeovian’s pipeline diversification and long‑term growth prospects.

Deal Summary

Aeovian Pharmaceuticals, a clinical-stage biopharma based in Berkeley, announced a $55 million Series B round led by Luma Group and CTI Life Sciences Fund, with participation from several other investors. The capital will be used to advance its lead candidate AV078 into Phase 2 trials for TSC‑refractory epilepsy.